AOD-9604 vs Sermorelin: A Research Reference
Where AOD-9604 and Sermorelin overlap in the literature, and where they do not, is the substance of this reference.
Compound profiles
AOD-9604 in the indexed record
AOD-9604 returns 16 indexed records on PubMed, a limited record with no registered studies currently listed on ClinicalTrials.gov.
Journals represented in the current index include Curr Opin Investig Drugs, Drug Test Anal, Expert Rev Proteomics, spanning 2004–2026.
- AOD-9604 Metabolic — Curr Opin Investig Drugs, 2004. PMID: 15134286
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- AOD-9604 does not influence the WADA hGH isoform immunoassay — Drug Test Anal, 2013. PMID: 24124033
- Human sports drug testing by mass spectrometry — Mass Spectrom Rev, 2017. PMID: 26213263
Sermorelin in the indexed record
Indexed output for Sermorelin stands at 332 records, a moderate literature, alongside 42 registered studies on ClinicalTrials.gov.
Publications carrying this compound include Clin Interv Aging, Drug Test Anal, J Am Acad Orthop Surg Glob Res Rev, spanning 2006–2026.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- Advances in the detection of growth hormone releasing hormone synthetic analogs — Drug Test Anal, 2021. PMID: 34665524
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? — Clin Interv Aging, 2006. PMID: 18046908
Classification and why it matters
AOD-9604 and Sermorelin sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for AOD-9604 describes conditions validated for AOD-9604: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Sermorelin without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Side-by-side research profile
| Parameter | AOD-9604 | Sermorelin |
|---|---|---|
| PubMed indexed records | 16 | 332 |
| Registered studies (ClinicalTrials.gov) | 0 | 42 |
| Literature depth | Emerging | Moderate |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
How the literature differs
The indexed record is not symmetrical between these two compounds. Sermorelin carries 316 more indexed records than AOD-9604, which means published methodology, characterisation data and replication attempts are more readily located for Sermorelin. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (0 vs 42) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Verification and documentation
What is in the vial is established by lot-specific analytics, not by label text. HPLC gives purity as a share of total peak area; mass spectrometry confirms the molecular weight matches the intended sequence. Neither substitutes for the other.
Physical handling notes
Both arrive lyophilised. Standard practice keeps the unopened vial at -20°C, protected from light, and defers reconstitution until the point of use. Solution-phase stability is the limiting factor in most protocols, not powder-phase stability.
Repeated freezing and thawing is the most common avoidable source of degradation.
Selecting between them for a study design
AOD-9604 and Sermorelin are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (Sermorelin) generally offers more methodological precedent.
Frequently asked questions
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Are AOD-9604 and Sermorelin the same compound?
No. They are structurally distinct research compounds with separate literature records — 16 indexed records for AOD-9604 and 332 for Sermorelin.
Which of AOD-9604 or Sermorelin has more published research?
Sermorelin, with 332 indexed PubMed records against 16.
Related references
- AOD-9604 — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.